Irritable Bowel Syndrome Trial, Recruiting NCT06636513 Sponsor: Changi General Hospital Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT06636513
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 21 and 70 years old (male or female)
  • People who have been diagnosed with Irritable Bowel Syndrome with diarrhoea (IBS-D), mixed-type IBS (IBS-M), or functional diarrhoea, according to specific medical criteria called the Rome III definition — this involves stomach pain or discomfort on at least three days per month for the last three months, with symptoms starting at least six months ago, along with certain patterns in bowel habits (confirm with trial site)
  • People who have had a colonoscopy with a normal (negative) result within the past five years
  • People who are able to read and complete questionnaires
  • People who have provided written consent to participate

Who may not be able to join:

  • People with known conditions such as inflammatory bowel disease, lactose intolerance, coeliac disease, diabetes, thyroid problems, cancer, immune system disorders, autoimmune diseases, serious liver or kidney problems, or other known causes of stomach pain, diarrhoea, or constipation
  • People who have had surgery involving the small or large intestine, or who have had their appendix, uterus, or gallbladder removed in the past six months
  • People with a known serious mental illness, or whose psychiatric medication type or dose has changed in the last three months in a way that could affect their ability to make decisions about participating
  • People who have an active infection at the time of joining the trial
  • People who have used prebiotics, probiotics, antibiotics, or anti-inflammatory medicines within the past two weeks
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daphne Shih Wen Ang, Changi General Hospital

Phone: +65-64267815

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Changi General Hospital
Registry
ClinicalTrials.gov
Start date
20 March 2024
Est. completion
31 May 2025

Where this trial is recruiting

🇸🇬 Singapore

Primary endpoints

Change in microbiota (measured using Shannon index, Principal coordinate analysis, heatmaps) at month 3 after taking SMT04

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov